This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Phase 3 Recruiting 1000 enrolled Pfizer

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

Timeline

Start: 2025-09-28
Primary completion: 2028-09-12
Completion: 2034-12-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Mevrometostat	Small molecule	875 mg	Oral
Background	Enzalutamide	Other / unclassified	160 mg	Oral

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

Summary

Timeline

Drugs

Indications